Tratamento inédito contra AIDS usa medicação genética blogdacidadania.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blogdacidadania.com.br Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
VANCOUVER, BC, April 8, 2021 /PRNewswire/ - Bell employees needed confidence that their company was safely cleaning its facilities to protect them from COVID-19. Conventional methods for cleaning surfaces and areas were toxic, costly and dependent on hazmat contractor response time. We needed a proactive way to protect our employees from COVID-19 and to keep our company in full production to serve our customers, said Michael Shaw, vice president, Quality and Environmental Health and Safety for Bell.
That s when it reached out to Anthem One, Inc., a high-tech start-up in New Berlin, Wisconsin and the makers of the AOMI UC-V device.
Bell Uses Anthem One s AOMI UV-C Device to Keep Workspaces Safe for Employees apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
The CRISPR technology works like molecular scissors that can cut DNA at any given point, Endpoints News reported. In theory, a researcher could cut HIV from a patient s DNA. Still, some researchers are skeptical of the success because HIV is known to hide in hard-to-reach places.
When Excision s Kamel Khalili, a researcher at Temple, previously used this approach on mice infected with HIV, about one-third were cured.
He also led a study, published last year, that used CRISPR to successfully remove SIV a virus that behaves similarly to HIV from rhesus macaque monkeys, leaving researchers optimistic that they are getting closer to an HIV cure.
Published: Feb 17, 2021
SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) Excision BioTherapeutics Inc. (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simplex Virus, and EBT-107 for Hepatitis B.
The financing round was led by GreatPoint Ventures with support from existing investor ARTIS Ventures. New investors include Adjuvant Capital, Norwest Venture Partners, Anzu Partners, Cota Capital, WRVI Capital, IndusAge Partners, Loreda Holdings, and Olive Tree Capital. Ashok Krishnamurthi, Managing Partner at GreatPoint Ventures, will join the Board of Di